Health & Fitness
Health and Fitness
Health and Fitness
Tue, March 5, 2013Mon, March 4, 2013Sun, March 3, 2013Sat, March 2, 2013Fri, March 1, 2013Thu, February 28, 2013Wed, February 27, 2013Tue, February 26, 2013Mon, February 25, 2013Sun, February 24, 2013Sat, February 23, 2013Fri, February 22, 2013Thu, February 21, 2013Wed, February 20, 2013Tue, February 19, 2013Mon, February 18, 2013Sun, February 17, 2013Fri, February 15, 2013Thu, February 14, 2013Wed, February 13, 2013Tue, February 12, 2013Mon, February 11, 2013Basilea Receives Request to Place Repayment of CHF 48 Million From Capital Contribution Reserve on the Agenda of the Ordinary G
Published in Health and Fitness on Friday, February 22nd 2013 at 15:15 GMT by Market Wire
February 22, 2013 18:08 ET
Basilea Receives Request to Place Repayment of CHF 48 Million From Capital Contribution Reserve on the Agenda of the Ordinary General Meeting of Shareholders
BASEL, SWITZERLAND--(Marketwire - Feb 22, 2013) - Basilea Pharmaceutica Ltd. (
Basilea's board of directors will carefully evaluate the request.
Basilea's ordinary general meeting of shareholders is scheduled for April 9, 2013. The deadline for registration in the share register to vote at the ordinary general meeting of shareholders is March 28, 2013.
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
This press release can be downloaded from [ www.basilea.com ].
Press release (PDF):
[ http://hugin.info/134390/R/1680620/549123.pdf ]
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
[HUG#1680620]
